N-Propionyl-3,4-dichlor-benzylamin | 17847-49-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-Propionyl-3,4-dichlor-benzylamin
• 英文别名: N-(3,4-dichlorobenzyl)propanamide；N-[(3,4-dichlorophenyl)methyl]propanamide
• CAS: 17847-49-3
• 化学式: C₁₀H₁₁Cl₂NO
• mdl: MFCD03377925
• 分子量: 232.109
• InChiKey: DIAQLYQNZGJGSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  丙酸酐 、 3,4-二氯苄胺 生成 N-Propionyl-3,4-dichlor-benzylamin
  参考文献：
  名称：

  Pagani; Baruffini; Borgna, Farmaco, Edizione Scientifica, 1967, vol. 22, # 12, p. 1019 - 1036

  摘要：

  DOI：

文献信息

• [EN] BIARYL AMIDE OR UREA DERIVATIVES AS TRPV1 LIGANDS<br/>[FR] DÉRIVÉS DE BIARYL AMIDE OU D'URÉE EN TANT QUE LIGANDS DE TRPV1
  申请人：UNIV SIENA

  公开号：WO2015162216A1

  公开（公告）日：2015-10-29

  The present invention relates to high affinity compounds, able to bind the transient receptor potential cation channel, subfamily Vanilloid, type 1 or TRPV1. Being this receptor involved in pain processing and neurogenic inflammatory responses and being up-regulated during chronic pain conditions, the compounds of the invention find particular application in all medical conditions involving said receptors, in particular as agents for pain therapy and/or anti-inflammatory and/or cluster headache therapy and/or anti-oxidant and/or anti-cancer therapy. Moreover, the chemical structure of these compounds provides the opportunity of developing new radiotracers for Positron Emission Tomography (PET) imaging. These radiotracers are of great relevance for mapping TRPV1 receptors in (patho)physiological conditions.

  本发明涉及高亲和力化合物，能够结合瞬时受体电位阳离子通道，亚家族Vanilloid，类型1或TRPV1。由于这种受体参与疼痛处理和神经源性炎症反应，并且在慢性疼痛情况下上调，本发明的化合物在涉及该受体的所有医学状况中找到特定应用，特别是作为疼痛治疗和/或抗炎疗法和/或群集性头痛治疗和/或抗氧化剂和/或抗癌疗法的药物。此外，这些化合物的化学结构为开发新的正电子发射断层扫描（PET）成像的放射示踪剂提供了机会。这些放射示踪剂对于在（病理）生理条件下映射TRPV1受体具有重要意义。
• QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS
  申请人：Collingwood Stephen Paul

  公开号：US20100041887A1

  公开（公告）日：2010-02-18

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的化合物，其以盐或双离子形式存在，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉乙酰胆碱M3受体介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• Quinuclidine derivatives binding to mucarinic m3 receptors
  申请人：Collingwood Paul Stephen

  公开号：US20070060563A1

  公开（公告）日：2007-03-15

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的盐或双电离形式的化合物，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉型M3受体介导的病症。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• US8168654B2
  申请人：——

  公开号：US8168654B2

  公开（公告）日：2012-05-01
• Pagani; Baruffini; Borgna, Farmaco, Edizione Scientifica, 1967, vol. 22, # 12, p. 1019 - 1036
  作者：Pagani、Baruffini、Borgna、Gialdi

  DOI：——

  日期：——